Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

JOURNAL ARTICLE published 10 July 2010 in Journal of Clinical Oncology

Authors: David W. Miles | Arlene Chan | Luc Y. Dirix | Javier Cortés | Xavier Pivot | Piotr Tomczak | Thierry Delozier | Joo Hyuk Sohn | Louise Provencher | Fabio Puglisi | Nadia Harbeck | Guenther G. Steger | Andreas Schneeweiss | Andrew M. Wardley | Andreas Chlistalla | Gilles Romieu